Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Heterogeneity and Scoring Reproducibility of Folate Receptor 1 Immunohistochemistry in High-grade Serous Carcinoma.
Journal: International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
Published: June 11, 2025
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer.
Journal: Gynecologic oncology
Published: April 05, 2025
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design.
Journal: Future oncology (London, England)
Published: February 06, 2025
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Journal: Gynecologic oncology
Published: July 01, 2024
Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen.
Journal: British journal of clinical pharmacology
Published: June 28, 2024
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: June 10, 2024
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Journal: The New England journal of medicine
Published: December 06, 2023
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Journal: Gynecologic oncology
Published: November 29, 2023
Reply to Z.R. McCaw et al.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 03, 2023
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor-α positive ovarian cancer: The antibody-drug conjugate, payload and metabolite.
Journal: British journal of clinical pharmacology
Published: February 01, 2023
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 30, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Journal: Gynecologic oncology
Published: October 03, 2022
Last Updated: 09/26/2026